30077-88-4

Basic information

• Product Name: 3-morpholino-2-veratrylacrylonitrile
• Synonyms: 3-morpholino-2-veratrylacrylonitrile;3,4-Dimethoxy-α-(morpholinomethylene)benzenepropiononitrile
• CAS NO: 30077-88-4
• Molecular Formula: C₁₆H₂₀N₂O₃
• Molecular Weight: 288.3416
• EINECS: 250-031-0
• Mol File: 30077-88-4.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 468.4°Cat760mmHg
• Flash Point: 237.1°C
• Appearance: /
• Density: 1.187g/cm³
• Vapor Pressure: 6.02E-09mmHg at 25°C
• Refractive Index: 1.586
• CAS DataBase Reference: 3-morpholino-2-veratrylacrylonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 3-morpholino-2-veratrylacrylonitrile(30077-88-4)
• EPA Substance Registry System: 3-morpholino-2-veratrylacrylonitrile(30077-88-4)

Safety Data

• Hazardous Substances Data: 30077-88-4(Hazardous Substances Data)

Usage

InChI:InChI=1/C16H20N2O3/c1-19-15-4-3-13(10-16(15)20-2)9-14(11-17)12-18-5-7-21-8-6-18/h3-4,10,12H,5-9H2,1-2H3/b14-12-

Upstream product

• 4542-47-6 3-Morpholin-4-yl-propionitrile 
• 120-14-9 3,4-dimethoxy-benzaldehyde 

Downstream Products

• 5355-16-8 diaveridine 
• 30077-75-9 3-anilino-2-veratrylacrylonitrile 

Relevant articles and documents

Halogenated trimethoprim derivatives as multidrug-resistant Staphylococcus aureus therapeutics

Incorporation of halogen atoms to drug molecule has been shown to improve its properties such as enhanced in membrane permeability and increased hydrophobic interactions to its target. To investigate the effect of halogen substitutions on the antibacterial activity of trimethoprim (TMP), we synthesized a series of halogen substituted TMP and tested for their antibacterial activities against global predominant methicillin resistant Staphylococcus aureus (MRSA) strains. Structure-activity relationship analysis suggested a trend in potency that correlated with the ability of the halogen atom to facilitate in hydrophobic interaction to saDHFR. The most potent derivative, iodinated trimethoprim (TMP-I), inhibited pathogenic bacterial growth with MIC as low as 1.25 μg/mL while the clinically used TMP derivative, diaveridine, showed resistance. Similar to TMP, synergistic studies indicated that TMP-I functioned synergistically with sulfamethoxazole. The simplicity in the synthesis from an inexpensive starting material, vanillin, highlighted the potential of TMP-I as antibacterial agent for MRSA infections.